Immunocompromised people require additional protection against COVID-19 because they are unlikely to mount a full response to COVID-19 vaccinations and have a higher risk of severe outcomes if infected. In December 2021, an Emergency Use Authorization (EUA) was granted for pre-exposure prophylaxis in immunocompromised people. Here, Dr. Jonathan Li reviews trial data, EUA criteria, efficacy against the Omicron variant, and patient prioritization strategies.

Many of the resources discussed during this program can be found on the COVID-19 Clinical Resource Center at www.ExchangeCME.com/COVIDPOCResources.

Please view other activities in this series on the series landing page at www.ExchangeCME.com/group/COVIDPOCSeries.

свернуть